% | $
Quotes you view appear here for quick access.

Theravance, Inc. Message Board

  • jupiter_symphony33 jupiter_symphony33 Mar 14, 2014 4:56 PM Flag

    baird reiterates outperform ($44 price target)

    Baird analyst Brian Skorney has increased confidence in the potential of Theravance Inc. (NASDAQ: THRX) Anoro following randomized COPD studies. He reiterated an Outperform rating and price target of $44.00.

    Skorney commented, "With positive results across three studies against either dose of fluticasone propionate/salmeterol, Anoro continues to build its safety and efficacy profile against key competitors. Aside from the advantage Anoro has with QD dosing, we believe the demonstrated superior efficacy to Advair adds further differentiation in the COPD market."

9.810.00(0.00%)Jan 8 4:00 PMEST